Year: 2023

VitalHub Ranked Number 421 Fastest-Growing Company in North America on the 2023 Deloitte Technology Fast 500™

Written by Customer Service on November 9, 2023. Posted in Public Companies.

Attributes 291% Revenue Growth to the company’s ability to meet the transformative digital needs of healthcare providers globally. TORONTO, Nov. 09, 2023 (GLOBE NEWSWIRE) — VitalHub Corp. (the “Company” or “VitalHub”) (TSX: VHI) (OTCQX:VHIBF) today announced it ranked 421st on the Deloitte Technology Fast 500™, a ranking of the fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies in North America, now in its 29th year. VitalHub grew 291% during this period. VitalHub’s chief executive officer, Dan Matlow, credits the company’s ability to meaningfully impact client and patient outcomes by meeting the transformative digital needs of our healthcare customers around the world with the company’s 291% revenue growth. Dan Matlow said, “We are grateful for the growing recognition...

SAB Biotherapeutics to Present at Piper Sandler Healthcare Conference

Written by Customer Service on November 9, 2023. Posted in Public Companies.

SIOUX FALLS, S.D., Nov. 09, 2023 (GLOBE NEWSWIRE) — SAB Biotherapeutics, Inc. (Nasdaq: SABS), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing fully-human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today announced that Eddie J. Sullivan, Ph.D., co-founder, President and Chief Executive Officer of SAB Biotherapeutics will present at the 35th Annual Piper Sandler Healthcare Conference, taking place from November 28 to November 30, 2023 at The Lotte New York Palace in New York. The conference is an invitation only event that brings together key industry executives, investors and other professionals to provide multiple perspectives, investigate critical trends and identify leaders in the healthcare space. Dr. Sullivan’s...

Revival Gold Announces Non-Brokered Private Placement Financing

Written by Customer Service on November 9, 2023. Posted in Public Companies.

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES TORONTO, Nov. 09, 2023 (GLOBE NEWSWIRE) — Revival Gold Inc. (TSXV: RVG, OTCQX: RVLGF) (“Revival Gold” or the “Company”), announces its intention to complete a non-brokered private placement of up to 11,000,000 units of the Company (the “Units”) at a price of C$0.35 per Unit (the “Issue Price”) for gross proceeds of up to C$3,850,000 (the “Financing”). Each Unit will be comprised of one (1) common share of the Company (a “Common Share”) and one half of one (0.5) Common Share purchase warrant (each whole warrant, a “Warrant”). Each Warrant will entitle the holder thereof to acquire one (1) Common Share (a “Warrant Share”) at an exercise price of C$0.45 per Warrant Share at any time for a period of thirty-six (36) months following the...

AYR Cannabis Dispensary Now Carrying Kiva Camino Gummies in Florida

Written by Customer Service on November 9, 2023. Posted in Public Companies.

MIAMI, Nov. 09, 2023 (GLOBE NEWSWIRE) — AYR Cannabis Dispensary, a cannabis retail chain owned by AYR Wellness, Inc. (CSE: AYR.A, OTCQX: AYRWF) (“AYR” or the “Company”), a leading vertically integrated U.S. multi-state cannabis operator (“MSO”), today launched Kiva Confections Camino Soft Chews across its network of 62+ Florida dispensaries. The launch follows the Company’s entrance into a three-year, exclusive licensing and retail agreement in Florida with Kiva Confections, a global leader in cannabis edibles. “I am thrilled that AYR Cannabis Dispensary locations across Florida will now be carrying Camino Soft Chews by Kiva Confections,” said Sevi Borrelli, AYR’s General Manager, Florida. “Our Florida patients have been asking for more options in the edible category, and the Camino brand encapsulates all of the qualities of a...

Red White & Bloom Launches Platinum® in Ohio Following Successful Vote for Adult-Use Marijuana Legalization

Written by Customer Service on November 9, 2023. Posted in Public Companies.

TORONTO, Nov. 09, 2023 (GLOBE NEWSWIRE) — Red White & Bloom Brands Inc. (CSE: RWB and OTC: RWBYF) (“RWB” or the “Company”) is excited to announce its entry into the rapidly growing Ohio cannabis market through the execution of a licensing arrangement with a first mover, vertically integrated Ohio distributor. This strategic partnership allows RWB to leverage the distributor’s retail network to introduce its renowned Platinum Vape cartridges and disposable vapes, available in various formats, across more than ninety licensed retail locations in the state. Colby De Zen, President of RWB, expressed enthusiasm about the Company’s recent entry into Ohio. “RWB takes great pride in expanding its presence in emerging adult-use markets in the United States. Ohio represents another pivotal entry point for RWB, allowing us to leverage...

Wave Life Sciences Reports Third Quarter 2023 Financial Results and Provides Business Update

Written by Customer Service on November 9, 2023. Posted in Earnings Releases And Operating Results.

Initiated RestorAATion clinical program for WVE-006, industry’s first-ever RNA editing clinical candidate, following approval of CTAs; dosing on track for 4Q 2023 and first-in-human proof-of-mechanism data anticipated in 2024 On track to deliver dystrophin data from potentially registrational FORWARD-53 trial of WVE-N531 in 2024 Enrollment complete in 30 mg multi-dose cohort of SELECT-HD with clinical data for decision-making on track for 2Q 2024; achieved milestone from Takeda collaboration for NHP study that further reinforces productive distribution of WVE-003 to deep brain regions Presented preclinical proof-of-concept data for new, wholly owned GalNAc-siRNA INHBE program for metabolic disorders, including obesity; leads identified and clinical candidate selection expected in 4Q 2024 Cash and cash equivalents of $140 million as of...

Verrica Pharmaceuticals Reports Third Quarter 2023 Financial Results

Written by Customer Service on November 9, 2023. Posted in Earnings Releases And Operating Results.

– Strong awareness and interest in prescribing YCANTH™ among dermatologists and pediatricians – – Over 112 million lives covered to date on commercial insurance and managed Medicaid plans – – Conference Call Scheduled for Today at 8:30 am ET – WEST CHESTER, Pa., Nov. 09, 2023 (GLOBE NEWSWIRE) — Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced financial results for the third quarter ended September 30, 2023. “Following the U.S Food and Drug Administration approval of YCANTH™ for the treatment of molluscum in July, we continue to build momentum across our commercial operations,” said Ted White, Verrica’s President and Chief Executive Officer. “As the only FDA-approved product for the treatment...

LanzaTech Global, Inc. Announces Third Quarter 2023 Financial Results

Written by Customer Service on November 9, 2023. Posted in Earnings Releases And Operating Results.

Operating revenues of $19.6 million for third quarter 2023, an increase of 143% over third quarter 2022 Continued progress starting up commercial-scale plants with successful startup at partner IndianOil Corporation’s refinery off-gas facility in India Current cash, restricted cash, and investments of $136.9 million with lower quarterly cash burn compared to first two quarters of 2023 CHICAGO, Nov. 09, 2023 (GLOBE NEWSWIRE) — LanzaTech Global, Inc. (Nasdaq: LNZA) (“LanzaTech” or the “Company”), the carbon recycling company transforming waste carbon into sustainable raw materials, today reported its financial and operating results for the third quarter of 2023. Financial Results Summary In the third quarter of 2023, revenue totaled $19.6 million, reflecting an increase of 143% compared to $8.1 million in the third quarter of 2022,...

Intellia Therapeutics Announces Third Quarter 2023 Financial Results and Highlights Recent Company Progress

Written by Customer Service on November 9, 2023. Posted in Earnings Releases And Operating Results.

FDA cleared NTLA-2001 IND application for first in vivo CRISPR candidate to enter late-stage clinical development; on track to initiate the MAGNITUDE pivotal Phase 3 trial in patients with transthyretin (ATTR) amyloidosis with cardiomyopathy by year-end Clinical data presented from over 60 patients with ATTR amyloidosis demonstrated consistent, deep and durable serum TTR reduction after a single dose of NTLA-2001; greater than 90% median serum TTR reduction On track to complete enrollment of the NTLA-2002 Phase 2 study for the treatment of hereditary angioedema (HAE) in Q4 2023 Plan to submit a Clinical Trial Application (CTA) in Q1 2024 for NTLA-3001, an in vivo insertion candidate in development for the treatment of alpha-1 antitrypsin deficiency (AATD)-associated lung disease Intellia and Regeneron expand research collaboration...

Compass Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Written by Customer Service on November 9, 2023. Posted in Earnings Releases And Operating Results.

Opened 29 clinical sites and continue to enroll patients in COMPANION-002, a U.S. Phase 2/3 study of CTX-009 in combination with Paclitaxel in patients with advanced biliary tract cancers (BTC); top line data from this study is expected in the second half of 2024 Continue to enroll and follow patients in COMPANION-003, a U.S. Phase 2 study of CTX-009 (DLL4 /VEGF-A bispecific antibody) in patients with advanced colorectal cancer (CRC); initial data from this study is expected before the end of the year Received IND clearance for CTX-8371, a next generation bispecific checkpoint inhibitor that simultaneously targets PD-1 and PD-L1; anticipate initiating a first-in-human clinical study in the fourth quarter of 2023 Announces a CEO succession plan; Vered Bisker-Leib, PhD, Compass President and COO, to transition to Compass Chief Executive...

Year: 2023

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals